Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide

British Journal of Cancer

Volumn 89, Issue 5, 2003, Pages 922-929

  Kanzawa, T ^a,b   Germano, I M ^a   Kondo, Y ^a,b   Ito, H ^a   Kyo, S ^c   Kondo, S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Glioma; hTERT; Telomerase; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; ALKYLGUANINE ALKYLTRANSFERASE; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE INHIBITOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SP1; TRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DEATH; CELL DIVISION; DACARBAZINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION; GLIOMA; GUANINE; HUMANS; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0141730399     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601193     Document Type: Article

References (47)

1. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67: 1299-1302
2. Black AR, Azizkhan-Clifford J (1999) Regulation of E2F: a family of transcription factors involved in proliferation control. Gene 237: 281-302
3. Black AR, Black JD, Azizkhan-Clifford J (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188: 143-160
4. Blackburn EH, Greider CW, Henderson E, Lee MS, Shampay J, Shippen-Lentz D (1989) Recognition and elongation of telomeres by telomerase. Genome 31: 553-560
5. Chadeneau C, Siegel P, Harley CB, Muller WJ, Bacchetti S (1995) Telomerase activity in normal and malignant murine tissues. Oncogene 11: 893-898
6. Chen F, Zhang F, Rao J, Studzinski GP (2000) Ectopic expression of truncated Sp1 transcription factor prolongs the S phase and reduces the growth rate. Anticancer Res 20A: 661-667
7. Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV (2001) Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 108: 1541-1547
8. 6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6: 389-393
9. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341
10. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051
11. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87: 5368-5372
12. Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E, Graziani G (1997) Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3: 579-585
13. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J (1995) The RNA component of human telomerase. Science 269: 1236-1241
14. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, Bigner DD, Schold Jr SC (1995) Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55: 2853-2857
15. Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597
16. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399
17. Gidoni D, Kadonaga JT, Barrera-Saldana H, Takahashi K, Chambon P, Tjian R (1985) Bidirectional SV40 transcription mediated by tandem Sp1 binding interactions. Science 230: 511-517
18. Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD (2000) Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 21: 1485-1492
19. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW (1994) Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 59: 307-315
20. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I, Robinson MO (1997) A mammalian telomerase-associated protein. Science 275: 973-977
21. Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, Arita N (1998) Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 58: 2117-2125
22. Horikawa I, Cable PL, Afshari C, Barrett JC (1999) Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 59: 826-830
23. Imataka H, Sogawa K, Yasumoto K, Kikuchi Y, Sasano K, Kobayashi A, Hayami M, Fujii-Kuriyama Y (1992) Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J 11: 3663-3671
24. Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, Nakashima Y, Shirasuna K, Sueishi K (2000) Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 60: 6531-6536
25. Kadonaga JT, Carner KR, Masiarz FR, Tjian R (1987) Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 51: 1079-1090
26. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015
27. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S, Kondo S (2001) Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61: 5796-5802
28. Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S (2000) Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther 7: 2071-2079
29. Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, Liu J, Haqqi T, Nishiyama A, Villeponteau B, Cowell JK, Barna BP (1998a) Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 12: 801-811
30. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK (1998b) Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16: 2243-2248
31. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M (2000) Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28: 669-677
32. Lee D, Kim HZ, Jeong KW, Shim YS, Horikawa I, Barrett JC, Choe J (2002) Human Papillomavirus E2 down-regulates the human telomerase reverse transcriptase promoter. J Biol Chem 277: 27748-27756
33. Lin Z, Lim S, Viani MA, Sapp M, Lim MS (2001) Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am J Pathol 159: 711-719
34. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T. (2001) Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61: 3053-3061
35. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795
36. Mukai S, Kondo Y, Koga S, Komata T, Barna BP, Kondo S (2000) 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 60: 4461-4467
37. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959
38. Nakayama J, Saito M, Nakamura H, Matsuura A, Ishikawa F (1997) TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88: 875-884
39. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-942
40. Pieper RO, Patel S, Ting SA, Futscher BW, Costello JF (1996) Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J Biol Chem 271: 13916-13924
41. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54: 3793-3799
42. Sawant SG, Gregoire V, Dhar S, Umbricht CB, Cvilic S, Sukumar S, Pandita TK (1999) Telomerase activity as a measure for monitoring radio-curability of tumor cells. FASEB J 13: 1047-1054
43. Shay JW, Wright WE (1996) Telomerase activity in human cancer. Curr Opin Oncol 8: 66-71
44. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557
45. Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G. (2003) Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. Mol Pharmacol 63: 192-202
46. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74: 1030-1036
47. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771